Massachusetts Financial Services CO Macrogenics Inc Transaction History

Massachusetts Financial Services CO

$321 Billion
Q1 2024

A detailed history of Massachusetts Financial Services CO transactions in Macrogenics Inc stock. As of the latest transaction made, Massachusetts Financial Services CO holds 40,340 shares of MGNX stock, worth $171,445. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,340

Previous 165,107 75.57%

Holding current value

$171,445

Previous $1.59 Million 62.66%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$9.77 - $21.47 $1.22 Million - $2.68 Million	-124,767 Reduced 75.57%	40,340 $593,000
Q4 2023 Feb 08, 2024	SELL	$4.48 - $10.11 $130,354 - $294,170	-29,097 Reduced 14.98%	165,107 $1.59 Million
Q3 2023 Nov 08, 2023	BUY	$4.48 - $6.19 $215,568 - $297,850	48,118 Added 32.94%	194,204 $904,000
Q2 2023 Aug 09, 2023	SELL	$4.62 - $7.54 $15,902 - $25,952	-3,442 Reduced 2.3%	146,086 $781,000
Q1 2023 May 10, 2023	BUY	$4.82 - $7.24 $245,487 - $368,740	50,931 Added 51.66%	149,528 $1.07 Million

Q4 2022 Feb 13, 2023	BUY	$5.62 - $6.98 $11,723 - $14,560	2,086 Added 2.16%	98,597 $661,000
Q3 2022 Nov 09, 2022	SELL	$3.01 - $5.22 $2,648 - $4,593	-880 Reduced 0.9%	96,511 $334,000
Q2 2022 Aug 09, 2022	BUY	$2.25 - $9.99 $1,109 - $4,925	493 Added 0.51%	97,391 $287,000
Q1 2022 May 11, 2022	BUY	$8.12 - $16.9 $151,023 - $314,323	18,599 Added 23.75%	96,898 $854,000
Q4 2021 Feb 10, 2022	BUY	$15.91 - $21.88 $634,713 - $872,880	39,894 Added 103.88%	78,299 $1.26 Million
Q3 2021 Nov 10, 2021	SELL	$19.74 - $28.7 $830,639 - $1.21 Million	-42,079 Reduced 52.28%	38,405 $804,000
Q2 2021 Aug 13, 2021	SELL	$20.49 - $35.63 $417,565 - $726,103	-20,379 Reduced 20.2%	80,484 $2.16 Million
Q1 2021 May 13, 2021	SELL	$18.99 - $33.2 $227,025 - $396,906	-11,955 Reduced 10.6%	100,863 $3.21 Million
Q4 2020 Feb 12, 2021	SELL	$19.41 - $26.0 $21,972 - $29,432	-1,132 Reduced 0.99%	112,818 $2.58 Million
Q3 2020 Nov 12, 2020	SELL	$24.69 - $31.6 $894,271 - $1.14 Million	-36,220 Reduced 24.12%	113,950 $2.87 Million
Q2 2020 Aug 11, 2020	SELL	$5.2 - $29.12 $19,895 - $111,413	-3,826 Reduced 2.48%	150,170 $4.19 Million
Q1 2020 May 14, 2020	BUY	$4.28 - $12.11 $104,325 - $295,181	24,375 Added 18.8%	153,996 $896,000
Q4 2019 Feb 13, 2020	SELL	$7.95 - $12.27 $111,387 - $171,914	-14,011 Reduced 9.75%	129,621 $1.41 Million
Q3 2019 Nov 05, 2019	BUY	$12.44 - $17.48 $846,653 - $1.19 Million	68,059 Added 90.06%	143,632 $1.83 Million
Q2 2019 Aug 14, 2019	BUY	$14.51 - $19.71 $152,746 - $207,487	10,527 Added 16.18%	75,573 $1.28 Million
Q1 2019 May 13, 2019	SELL	$11.11 - $25.6 $341,843 - $787,686	-30,769 Reduced 32.11%	65,046 $1.17 Million
Q4 2018 Feb 08, 2019	BUY	$11.75 - $21.42 $465,358 - $848,339	39,605 Added 70.46%	95,815 $1.22 Million
Q3 2018 Oct 25, 2018	SELL	$19.26 - $23.46 $2,523 - $3,073	-131 Reduced 0.23%	56,210 $1.21 Million
Q2 2018 Jul 30, 2018	BUY	$19.78 - $24.67 $1.11 Million - $1.39 Million	56,341 New	56,341 $1.16 Million

Others Institutions Holding MGNX

# of Institutions

170

Shares Held

62.4M

Call Options Held

819K

Put Options Held

79.4K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $261M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.

Account

Massachusetts Financial Services CO Macrogenics Inc Transaction History